Search

Displaying results 4031 - 4040 of 10000 in total
  1. Drug

    Seletracetam

    go.drugbank.com/drugs/DB05885
    Investigational

    Food and Drug Administration (FDA) investigated as treatment of epilepsy and partial epilepsy however its development had been put on hold in July 2007. … Seletracetam was in Phase II clinical trials under the supervision of the U.S.

  2. Drug

    Pirtobrutinib

    go.drugbank.com/drugs/DB17472
    ApprovedInvestigational

    A256758] Unlike BTK covalent inhibitors, such as [ibrutinib], that bind to the cysteine 481 (Cys481) amino acid within the active site of BTK, the inhibitory activity of pirtobrutinib is maintained even in … [L44863,L44873] In December 2025, pirtobrutinib received traditional FDA approval for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) previously

  3. Drug

    Alacepril

    go.drugbank.com/drugs/DB21364
    Experimental

    The usage of the INN stem '-pril' in the name indicates that Alacepril is a angiotensin-converting enzyme inhibitor. Alacepril has a monoisotopic molecular weight of 406.16 Da.

    Categories: Agents Acting on the Renin-Angiotensin System
  4. Drug

    Zolasartan

    go.drugbank.com/drugs/DB20140
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Agents Acting on the Renin-Angiotensin System
  5. Drug

    Fluphenazine

    go.drugbank.com/drugs/DB00623
    Approved

    A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.

  6. Drug

    Linsitinib

    go.drugbank.com/drugs/DB06075
    Investigational

    An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.

  7. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

  8. Drug

    Influenza B virus B/Darwin/7/2019 antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB15709
    ApprovedWithdrawn

    Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. … In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques.

  9. Drug

    Evogliptin

    go.drugbank.com/drugs/DB12625
    Investigational

    Evogliptin has been used in trials studying the treatment and screening of Osteoporosis, Renal Impairment, Type 2 Diabetes Mellitus, Diabetes Mellitis Type 2, and Diabetes Mellitus, Type 2.

    Categories: Drugs Used in Diabetes
  10. Drug

    Diloxanide

    go.drugbank.com/drugs/DB08792
    Experimental

    Diloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.